Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.

World J Gastroenterol · 2020 · PMC7438196 · PMID 32874058

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

This result may be consistent with the findings of a meta-analysis conducted by Casadei et al[ 16 ] who highlighted a clear trend favoring lenvatinib over sorafenib (HR, 0.82; 95%CI: 0.60–1.15) in HBV-positive patients.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.